THE NEW MONCLER INVESTOR RELATIONS APP IS NOW AVAILABLE
The Group has always believed in research and innovation as key drivers for continuous development and improvement. This belief goes beyond Company boundaries, as evidenced by Moncler’s commitment to promoting research in the medical and scientific sector, which it actively supports through funding and grants.
In 2018, a total of 600 million euros was earmarked for research grants and loans to support researchers at the Umberto Veronesi Foundation, and for donations to a number of associations and foundations involved in medical research and in supporting the ill, including Theodora and Anlaids.
The Umberto Veronesi Foundation was established in 2003 to support scientific research of excellence. Its promoters include 11 Nobel Prize winners, who form the Foundation’s Honorary Committee.
The Foundation supports medical and scientific research through grants for physicians and researchers involved in the most advanced fields of oncology, cardiology, and neuroscience. Since its inception, the Foundation has funded nearly 1,600 researchers involved in cutting-edge scientific projects.
Furthermore, it actively disseminates scientific information through conferences, projects with schools, awareness campaigns and publications.
In 2013, the Foundation launched the Pink is Good project to support breast cancer research and raise prevention awareness across the community. Moncler has actively supported this project since its inception, by donating part of the revenues generated by its main Italian retail stores during one day in October every year, and by handing out information brochures to clients to raise prevention awareness.
In 2018, once again, Moncler supported two of the Foundation’s researchers. One, from the University of Rome Tor Vergata, was involved in developing a self-
diagnosis test for breast cancer. The other, from the Italian National Institute for Cancer Research and Treatment in Milan, is studying the role of lung bacterial microflora in debilitating the immune system and allowing cancer to develop.
Moncler also continued to support the Foundation’s commitment to paediatric oncology by contributing to the Gold for Kids project, which aims to raise awareness of the delicate issue of paediatric and adolescent cancer. It promotes research and contributes to the development of innovative treatment protocols capable of delivering cutting-edge therapies and higher chances of recovery. In particular, Moncler continued to fund the five-year SAR-GEN 2016 protocol for the treatment of bone and soft tissue sarcomas, which account for 10-15% of childhood cancers. In 2018, in order to promote research into treatment as well as diagnosis, Moncler also funded a three-year study to assess the risk of secondary leukaemia in cancer survivors. The study will analyse the DNA of children who survived cancer, in order to develop a genetic test to predict risk and enable the early diagnosis of blood diseases resulting from cancer therapies.